Vikki Flemington

Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2

Richard A. Ward, Nicola Colclough, Mairi Challinor et al. · Journal of Medicinal Chemistry · 2015 · 105 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +15

Inhibition of cholesterol metabolism underlies synergy between mTOR pathway inhibition and chloroquine in bladder cancer cells

Matthew King, Ian G. Ganley, Vikki Flemington · Oncogene · 2016 · 88 citations · Full text

Medicine, Oncology, Pharmacology +17

Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)

Richard A. Ward, Mark J. Anderton, Paul A. Bethel et al. · Journal of Medicinal Chemistry · 2019 · 78 citations · Full text

Medicine, Oncology, Pharmacology +17

Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

Matthew J. Sale, Emma Minihane, Noel R. Monks et al. · Nature Communications · 2019 · 73 citations · Full text

Medicine, Cancer Biology, Oncology +17

Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point

Richard A. Ward, Paul A. Bethel, Calum Cook et al. · Journal of Medicinal Chemistry · 2017 · 52 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +16